FDA Targets Boosting Adverse Event Review ‘Accuracy And Efficiency’
This article was originally published in The Tan Sheet
Executive Summary
The agency seeks academic institutions and commercial organizations with tools to triage and review post-marketing adverse event drug product case reports submitted to the Adverse Event Reporting System.
You may also be interested in...
Drug Safety Business: Start-Up With AERS Filter Eyes Bisphosphonate Events
A small start-up company has developed a technique to filter the data in FDA’s Adverse Events Reporting System (AERS) database, which it says provides a more accurate analysis of adverse event reports.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.